Phenotypes Associated with This Genotype

Genotype
MGI:5485992

• Allelic Composition: Ptpmt1^tm2.1Ckq/Ptpmt1^tm2.1Ckq; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:194929 )

• most mice die within 2 to 3 weeks of pIpC treatment

hematopoietic system

hematopoietic system phenotype ( J:194929 )

N • hematopoietic stem cells in pIpC-treated mice exhibit normal apoptosis rates

decreased common myeloid progenitor cell number ( J:194929 )

• decreased bone marrow myeloid and lymphoid progenitors in pIpC-treated mice

anemia ( J:194929 )

• severe in pIpC-treated mice

abnormal common lymphocyte progenitor cell morphology ( J:194929 )

• decreased bone marrow myeloid and lymphoid progenitors in pIpC-treated mice

pancytopenia ( J:194929 )

• in pIpC-treated mice

increased hematopoietic stem cell number ( J:194929 )

• increased hematopoietic stem cells and multipotent progenitors in the bone marrow of pIpC-treated mice

abnormal hematopoietic stem cell physiology ( J:194929 )

• hematopoietic stem cells (HCS) from pIpC-treated mice fail to differentiate in colony forming assays

• cell-autonomous defect in differentiation and blocked repopulating capabilities in HCS from pIpC-treated mice

• HSCs from pIpC-treated mice accumulate at the G1 phase and exhibit enhanced entry of quiescence